赞比亚青蒿素部分耐药分子流行病学与临床研究
BACKGROUND: Artemisinin derivatives are central to first-line treatment of both uncomplicated and severe Plasmodium falciparum malaria. Emerging artemisinin partial resistance in east Africa threatens to spread across the continent.…
要点
- 赞比亚出现Pfkelch13 A724E突变,与青蒿素部分耐药临床相关。
- Kaoma地区A724E突变频率从2018年0%持续升至2026年79%。
- 携带A724E突变患者第3天原虫阳性率显著高于野生型。
核心结论
- 一种与青蒿素部分耐药临床相关的新发Pfkelch13突变正在赞比亚传播。
- 该地区急需更多临床评估。
研究设计与样本
- 2024年在赞比亚十省开展两项横断面研究,对Pfkelch13基因进行分型。
- 第一项研究从随机选取的家庭招募6-72月龄儿童。
- 第二项研究在100家选定卫生机构招募6月龄及以上有疟疾症状的患者。
- 在Kaoma招募12月龄及以上、镜检确诊且快速诊断试验阳性的恶性疟患者。
- 评估Pfkelch13基因型与青蒿素联合疗法治疗后第3天原虫阳性及离体双氢青蒿素敏感性的关联。
主要发现
- 西部省217株分离株中113株(52%,95%CI 45-59)携带Pfkelch13 A724E。
- 西北省184株分离株中94株(51%,95%CI 44-59)携带该突变。
临床怎么用
- 在赞比亚及周边地区应监测Pfkelch13 A724E突变以评估青蒿素部分耐药传播。
- 对青蒿素联合疗法治疗后第3天仍原虫阳性的患者应警惕耐药可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Artemisinin derivatives are central to first-line treatment of both uncomplicated and severe Plasmodium falciparum malaria. Emerging artemisinin partial resistance in east Africa threatens to spread across the continent. METHODS: In two cross-sectional studies conducted across the ten provinces of Zambia in 2024, we genotyped the artemisinin resistance-associated gene Pfkelch13. Children aged 6-72 months were recruited from randomly selected households in the first study, and patients 6 months or older presenting with malarial symptoms at 100 selected health facilities were recruited in the second study. In Kaoma, western Zambia, we recruited patients aged 12 months or older with microscopically confirmed P falciparum infection and a positive rapid diagnostic test. We evaluated the association between Pfkelch13 genotype and day 3 parasite positivity following treatment with artemisinin-based combination therapy, as well as ex-vivo parasite susceptibility to dihydroartemisinin (the active metabolite of artemisinin). We also assessed longitudinal changes in Pfkelch13 mutation prevalence in Kaoma using isolates collected during therapeutic efficacy studies and community surveys conducted from 2018 to 2026. FINDINGS: We identified a novel mutation, Pfkelch13 A724E, in 113 (52%) of 217 isolates (95% CI 45-59) from Western Province, 94 (51%) of 184 isolates (95% CI 44-59) from North-Western Province, and 229 (11·7%) of 1949 isolates countrywide. In Kaoma, 28% (21 of 75 [95% CI 18-40]) of patients carrying Pfkelch13 A724E mutant parasites before treatment were parasite-positive on day 3, compared with 0% (zero of 23; [0-15]) of patients with the wild-type allele (p=0·0026). Within the patients who were positive at day 3, the proportion of A724E mutant parasites increased significantly after treatment (p=0·0039). The prevalence of Pfkelch13 A724E in Kaoma increased steadily from 0% (0 of 15 isolates [95% CI 0-22]) in 2018 to 79% (132 of 167 [73-85]) in 2026. No significant ex-vivo growth inhibition was observed in Pfkelch13 A724E parasites after dihydroartemisinin exposure. INTERPRETATION: A novel Pfkelch13 mutation clinically associated with partial resistance to artemisinin is spreading in Zambia. Additional clinical evaluations are urgently needed in the region. FUNDING: The Gates Foundation (INV-048316).
引用
- Mwenda M, Oliveira R, Mambwe B, et al. Evidence of artemisinin partial resistance in Zambia: a molecular epidemiology and clinical study. Lancet Infect Dis. 2026. PMID: 42843387. doi:10.1016/S1473-3099(26)00478-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。